Companies / Peru
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Bioprospecting Dispute Puts New Twist On IP Rules
January 2007 | Legal NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Peruvian government officials are challenging US patents on pharmaceutical and supplement products derived from the maca plant, which is grown in Andes. The dispute concerns the intellectual property rights that adhere to commercial products made from plants and other substances often long used in traditional medicines. Pharmaceutical companies and the US government in particular argue that they take on the costly task of isolating and developing novel products based on substances long known to traditional peoples, and that the end commercial products represent wholly re-engineered products with novel qualities.